Asunción Hervás Morón-rekin lankidetzan egindako argitalpenak (6)

2024

  1. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)

    Practical Radiation Oncology, Vol. 14, Núm. 5, pp. e344-e352

2022

  1. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

    Frontiers in Oncology, Vol. 12

2018

  1. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 193-200

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1026-1033

2015

  1. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272